ArticleEJNMMI research2026
[
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundNeoadjuvant therapy (NAT) has become a standard treatment for HER2-positive breast cancer. However, patient responses vary substantially, and reliable methods for early response assessment are still lacking. This study aimed to evaluate the value of [68Ga]Ga-HER2 Affibody PET/CT for the early assessment of treatment outcome by predicting pathological complete response (pCR) in HER2-positive breast cancer.
results32 of the 54 enrolled patients achieved pCR (59.3%). Following two NAT cycles, [68Ga]Ga-HER2 Affibody PET/CT parameters decreased from baseline in all patients (P < 0.001). Early percentage changes in PET parameters (ΔSUV%, ΔSUL%, ΔTLA%, ΔTBR%) and their absolute values after the second NAT cycle were associated with pCR (r range: -0.658 to -0.273; P < 0.05). ΔTBR% demonstrated the best predictive value for pCR (AUC = 0.918), with 93.8% sensitivity and 86.4% specificity at a cutoff of -70.5%. In contrast, tumor size assessment based on RECIST 1.1 showed lower predictive performance, with a sensitivity of 56.3% (18/32) and a specificity of 45.5% (10/22).
conclusionThis study demonstrates the potential of [68Ga]Ga-HER2 Affibody PET/CT to predict NAT outcome early in HER2-positive breast cancer, which could facilitate subsequent treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.